Abstract | OBJECTIVES: BACKGROUND: AAD are prescribed in ARVC to prevent ventricular arrhythmias and control symptoms. However, there are no controlled clinical trials and knowledges regarding the efficacy of AAD in ARVC are limited. METHODS: RESULTS: Sixteen patients were taking AAD at baseline and 75 started at least one AAD during a median follow-up of 132 months [61-255]. A total of 37 patients experienced ≥1 MVA with a total count of 83 recurrent MVA. After adoption of a propensity score analysis, no AAD were associated with lower risk of recurrent MVA. However, if dosage of AAD was considered, beta-blockers at >50% target dose were associated with a significant reduction in the risk of MVA compared to patients not taking beta-blockers (HR 0.10, 95% CI 0.02-0.46, p = 0.004). CONCLUSIONS: In a large cohort of ARVC patients with a long-term follow-up, only beta-blockers administrated at >50% target dose were associated with lower risk of SCD/recurrent MVA.
|
Authors | Chiara Cappelletto, Caterina Gregorio, Giulia Barbati, Simona Romani, Antonio De Luca, Marco Merlo, Luisa Mestroni, Davide Stolfo, Gianfranco Sinagra |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 334
Pg. 58-64
(Jul 01 2021)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 33961942
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Elsevier B.V. All rights reserved. |
Chemical References |
|
Topics |
- Anti-Arrhythmia Agents
(adverse effects)
- Arrhythmias, Cardiac
(drug therapy)
- Arrhythmogenic Right Ventricular Dysplasia
(diagnosis, drug therapy, epidemiology)
- Death, Sudden, Cardiac
(epidemiology, prevention & control)
- Defibrillators, Implantable
- Heart Ventricles
- Humans
|